✦ LIBER ✦

Combined intravenous and oral mesna in outpatients treated with ifosfamide

✍ Scribed by Marshall P. Goren; Linda M. McKenna; Thomas L. Goodman

Publisher: Springer
Year: 1997
Tongue: English
Weight: 139 KB
Volume: 40
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s002800050673

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Urine mesna excretion after intravenous

Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children

✍ Marshall P. Goren; Sidnei Epelman; Dorothy A. Bush 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 210 KB

Phase II study of ifosfamide and mesna i

Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix

✍ Gregory P. Sutton; John A. Blessing; Leon Adcock; Kenneth D. Webster; Timothy De 📂 Article 📅 1989 🏛 Springer US 🌐 English ⚖ 223 KB

Comparison of N-acetylcysteine and mesna

Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors

✍ N. C. Munshi; P. J. Loehrer; S. D. Williams; C. Langefeld; G. Sledge; C. R. Nich 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 373 KB

Outpatient treatment with intravenous an

Outpatient treatment with intravenous antimicrobial therapy and oral levofloxacin in patients with febrile neutropenia and hematological malignancies

✍ Marcelo Bellesso; Silvia Figueiredo Costa; Luis Fernando Pracchia; Lucia Cristin 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 295 KB

A phase II trial of oral etoposide with

A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas

✍ Jorge E. Romaguera; M. Alma Rodriguez; Frederick B. Hagemeister; Peter McLaughli 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 491 KB

Phase II trial of ifosfamide and mesna i

Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8552

✍ Case, Delvyn C. ;Anderson, James ;Ervin, Thomas J. ;Gottlieb, Arlan 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB

Ifosfamide (1.25 g/m2 intravenously/day x 5) with mesna (20% of the ifosfamide dose x six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non-Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29% response rate (9/31) was observed (2 CR and